International Journal of COPD (Apr 2020)

Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis [Corrigendum]

  • Barjaktarevic IZ,
  • Buhr RG,
  • Wang X,
  • Hu S,
  • Couper D,
  • Anderson W,
  • Kanner RE,
  • Paine III R,
  • Bhatt SP,
  • Bhakta NR,
  • Arjomandi M,
  • Kaner RJ,
  • Pirozzi CS,
  • Curtis JL,
  • O'Neal WK,
  • Woodruff PG,
  • Han MK,
  • Martinez FJ,
  • Hansel N,
  • Wells JM,
  • Ortega VE,
  • Hoffman EA,
  • Doerschuk CM,
  • Kim V,
  • Dransfield MT,
  • Drummond MB,
  • Bowler R,
  • Criner G,
  • Christenson SA,
  • Ronish B,
  • Peters SP,
  • Krishnan JA,
  • Tashkin DP,
  • Cooper CB

Journal volume & issue
Vol. Volume 15
pp. 901 – 902


Read online

Barjaktarevic IZ, Buhr RG, Wang X, et al. Int J Chron Obstruct Pulmon Dis. 2019;14:2927– 2938. The authors have advised that there is an error in the Funding section on page 2935. The correct funding statement is as follows: FundingThis study was supported by R01HL125432-01A1 (MBD), T32HL007106-41 (RMB), and TL1TR001883-01 (RGB). SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN2682009 00014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200  900019C, and HHSN268200900020C) and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from  AstraZeneca/MedImmune, Bayer, Bellerophon Therapeutics, Boehringer-Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Forest Research Institute, Inc., GlaxoSmithKline, Grifols Therapeutics, Inc., Ikaria, Inc., Nycomed GmbH, Takeda Pharmaceutical Company, Novartis Pharmaceuticals Corporation, ProterixBio; Regeneron Pharmaceuticals, Inc., Sanofi, and Sunovion. The PRM analyses were supported by NHLBI HL122438 and HL138188. Mehrdad Arjomandi was supported by a grant from the Flight Attendant Medical Research Institute. The authors apologize for this error. Read the original article